The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine

[1]  G. Robert,et al.  Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients? , 2019, Autophagy.

[2]  M. Sekeres,et al.  Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. , 2017, Seminars in hematology.

[3]  R. Amaravadi,et al.  Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors , 2017, International journal of molecular sciences.

[4]  L. Liotta,et al.  Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia , 2017, Front. Pharmacol..

[5]  J. Carew,et al.  Drain the lysosome: Development of the novel orally available autophagy inhibitor ROC-325 , 2017, Autophagy.

[6]  J. Maciejewski,et al.  Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms , 2016, Leukemia.

[7]  Yingchun Han,et al.  Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis , 2016, Clinical Cancer Research.

[8]  M. Sekeres,et al.  More is better: combination therapies for myelodysplastic syndromes. , 2015, Best practice & research. Clinical haematology.

[9]  T. Curiel,et al.  Combined autophagy and HDAC inhibition , 2014, Autophagy.

[10]  F. Giles,et al.  Lucanthone Is a Novel Inhibitor of Autophagy That Induces Cathepsin D-mediated Apoptosis* , 2010, The Journal of Biological Chemistry.